Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalifrelimab in advanced or refractory cancer
NCT02694822Phase 2Completed
- Sponsor
- Agenus Inc.
- Start
- Apr 2016
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zalifrelimab in solid tumor (advanced stage), lymphoma, hepatocellular carcinoma (HCC), sponsored by Agenus Inc.. Started Apr 2016; status: completed.
02
Drugs
zalifrelimab
03
Conditions
solid tumor (advanced stage)lymphomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02694822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694822.